[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delirium-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delirium-treatment":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100612784","tavns-for-delirium-100612784",false,"NCT07258082","TaVNS for Delirium","Transauricular Vagus Nerve Stimulation (taVNS) for Delirium","Inclusion Criteria:\n\n* Stony Brook University Hospital inpatient, Age \\> 22\n* Right- handed\n* Screen positive for delirium on ICDSC instrument\n\nExclusion Criteria:\n\n* Severe neurologic disability including severe traumatic brain injury, severe permanent cognitive impairment\n* Pacemaker present\n* Implanted VNS stimulator present\n* Personal history of epilepsy\n* Facial or ear pain or trauma\n* Recent history of substance abuse\n* Any other medical condition that, in the judgment of the investigator, makes participation in the study unsafe.\n* Weight \\\u003C 40kg\n* Pregnant females\n* Intubated patient","ALL","22 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to test whether a non-invasive device called transauricular vagus nerve stimulation (taVNS) is safe, practical, and potentially helpful for patients in the hospital who develop delirium. Delirium is a state of confusion that often happens to people in the hospital who are sick or hurt. It can cause agitation, trouble paying attention and difficulty understanding what is happening. Delirium may slow overall recovery.\n\nThis study will focus on feasibility and safety. Researchers want to learn whether taVNS can be given safely to critically-ill patients, whether patients and staff can tolerate the treatments, and whether the device produces measurable changes in brain activity and brain oxygen levels.\n\nThe main questions this study aims to answer are:\n\n* Is it possible to deliver taVNS safely and consistently to patients in the ICU who have delirium?\n* Do patients tolerate the device without significant side effects or complications?\n* Does taVNS cause short-term changes in brain signals and oxygen levels that may suggest effects on brain function? This is an early feasibility study and there is no randomization or placebo group. All patients enrolled will receive taVNS in addition to their usual hospital care for delirium.\n\nWhat participants will do:\n\n* Be identified by their hospital care team and have a confirmed diagnosis of delirium.\n* Provide consent (or have a legally authorized representative provide consent if the patient cannot.)\n* Undergo brief assessments of thinking and attention (for example, the ICDSC test.)\n* Receive taVNS treatment using a small clip electrode placed on the ear.\n\n  * The device sends gentle electrical pulses to the nerve in the ear.\n  * Each session lasts about 30 minutes, given twice per day (morning and evening, with at least 6 hours between sessions).\n  * Treatment can continue for up to 7 days while the patient is in the ICU.\n* Be monitored during and after each session. The study team will check vital signs, examine the ear for irritation, and ask about any discomfort.\n* On the first day, researchers will also record brain signals (EEG) and brain oxygen levels before and during stimulation using FDA-approved hospital monitoring devices.\n\nPossible risks and discomforts:\n\n* Mild side effects are possible, such as tingling, a tickling or pricking feeling in the ear, or temporary skin redness where the clip is placed.\n* Serious side effects are not expected, but all patients will be closely monitored during and after each session to ensure safety.\n\nPossible benefits:\n\n• Patients may or may not experience personal benefit. The main benefit is helping researchers learn whether this treatment approach is safe and practical. In the future, taVNS could potentially become a new tool to help treat or prevent delirium in hospitalized patients.\n\nStudy size and duration:\n\n* The study will enroll a limited number of ICU patients with delirium at Stony Brook University Hospital.\n* Patients may take part for up to 7 days while hospitalized.\n\nWho can join:\n\n* Right-handed, adult patients in the ICU who are diagnosed with delirium.\n* People with certain medical conditions (such as brain bleeds, new strokes, pacemakers or other contraindications) may not be able to participate, for safety reasons.",[26,27],"Delirium Treatment","Delirium",[29,30,31,32,33],"delirium","tavns","transauricular vagus nerve stimulation","vagus nerve stimulation","transcutaneous vagus nerve stimulation","RECRUITING","2026-04-17",{"date":37,"type":38},"2026-04-22","ACTUAL",{"date":40,"type":38},"2025-09-26",{"date":42,"type":20},"2028-10",{"name":44,"class":45},"Stony Brook University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100488464","phase-4-pregabalin-versus-dexmedetomidine-for-delirium-treatment-after-coronary-artery-bypass-grafting-100488464","NCT05640453","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial","Inclusion Criteria:\n\n* CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).\n\nExclusion Criteria:\n\n* Patients who had history of psychiatric diseases; inability to communicate;\n* previous history of POD; preoperative sick sinus syndrome, allergy\u002Fsensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \\\u003C50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.\n* Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.","65 Years",{"count":56,"type":20},70,[58],"PHASE4","The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.",[61,26,62,63],"Pregabalin","Coronary Artery Bypass Grafting","Dexmedetomidine","2025-06-23",{"date":66,"type":38},"2025-06-25",{"date":68,"type":38},"2022-12-15",{"date":70,"type":20},"2026-05-15",{"name":72,"class":45},"Tanta University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":27,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100578330","management-of-non-pharmacologic-delirium-with-the-use-of-a-nursing-led-e-health-project-a-randonmized-controlled-trial-100578330","NCT06809894","Management of Non-pharmacologic Delirium With the Use of a Nursing-led E-health Project: a Randonmized Controlled Trial","Improvement of the Delirium Management in Adult Patients Hospitalized Through the Use of Non-pharmacological Interventions","Inclusion criteria:\n\n* Age over 80 years\n* Three risk factor to develop delirium, for example: sex (men), polypharmacy,urinary tract infections (UTIs) or strictures.\n* Admission in geriatric unit.\n* Have social support\n\nExclusion criteria:\n\n* Age under 80 years\n* Eseeable death on admission not caused by delirium or delirium diagnosis on admission.",true,"80 Years","130 Years",{"count":84,"type":20},65,[23],"Application of an action protocol focused on the application of non-pharmacological interventions for managing delirium in the process of prevention, diagnosis and treatment, evaluated using an e-health intervention, with a tablet to introduce on it the data about the prevention, diagnostic and treatment process of each recluted patient, in the Igualada Hospital Center, once a day.",[26,88,89],"Delirium Confusional State","Delirium in Old Age",[27,91,92,93,94,95],"SCA","CAM","Older pacient","non-pharmacologic treatment","nurse","NOT_YET_RECRUITING","2025-05-22",{"date":99,"type":38},"2025-05-29",{"date":101,"type":20},"2026-04-01",{"date":103,"type":20},"2027-06-15",{"name":105,"class":45},"Universitat de Lleida"]